SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma falls after its arm receives warning letter from USFDA for New Jersey facility

22 Oct 2020 Evaluate

Aurobindo Pharma is currently trading at Rs. 761.70, down by 43.60 points or 5.41% from its previous closing of Rs. 805.30 on the BSE.

The scrip opened at Rs. 809.80 and has touched a high and low of Rs. 809.80 and Rs. 754.00 respectively. So far 127614 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 967.60 on 10-Aug-2020 and a 52 week low of Rs. 281.15 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 815.00 and Rs. 754.00 respectively. The current market cap of the company is Rs. 44610.44 crore.

The promoters holding in the company stood at 52.01%, while Institutions and Non-Institutions held 36.68% and 11.31% respectively.

Aurobindo Pharma’s wholly owned step-down subsidiary -- AuroLife Pharma LLC has received a warning letter from US Food & Drug Administration (USFDA) for its oral solid manufacturing facility situated at Dayton, New Jersey. The company believes that the existing business from this facility will not be impacted. The Company will be engaging with the regulator and are fully committed in resolving this issue at the earliest.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1366.75 -18.90 (-1.36%)
20-Apr-2026 15:20 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1667.00
Dr. Reddys Lab 1231.75
Cipla 1228.35
Zydus Lifesciences 936.00
Lupin 2327.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×